San Francisco Business Times spoke to CEO Ben Bishop about Spirair’s mission to solve an unmet need in nasal septal deviation (NSD) and nasal airway obstruction (NAO) treatments. The article also delves into the company’s origin story including its roots in the Stanford Biodesign Fellowship and official company launch during the COVID-19 pandemic. In 2021, Spirair secured Series A funding from Sonder Capital and View Ventures to further its R&D efforts in preparation for its first FDA 510(k) clearance for the SeptAlign Implant.
Download the full article here.